New P2Y12 antagonists
AD Michelson - Current opinion in hematology, 2009 - journals.lww.com
AD Michelson
Current opinion in hematology, 2009•journals.lww.comThe clinical benefit of changing clopidogrel treatment based on platelet function tests, single-
nucleotide polymorphisms, or both is as yet unproven. Novel P2Y 12 antagonists are under
investigation to determine whether they can result in better, more rapid, or both,
antithrombotic effects than clopidogrel, without an unacceptable increase in hemorrhagic or
other side effects.
nucleotide polymorphisms, or both is as yet unproven. Novel P2Y 12 antagonists are under
investigation to determine whether they can result in better, more rapid, or both,
antithrombotic effects than clopidogrel, without an unacceptable increase in hemorrhagic or
other side effects.
Summary
The clinical benefit of changing clopidogrel treatment based on platelet function tests, single-nucleotide polymorphisms, or both is as yet unproven. Novel P2Y 12 antagonists are under investigation to determine whether they can result in better, more rapid, or both, antithrombotic effects than clopidogrel, without an unacceptable increase in hemorrhagic or other side effects.
Lippincott Williams & Wilkins